Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2016 06:00 ET | Source: Bioblast Pharma

Bioblast Announces Results of Trehalose Clinical Study

Pharmacokinetic Study in Healthy Volunteers Demonstrated Trehalose to be Safe and Well Tolerated at Twice the Dose Levels Used in Prior Clinical Studies Results Support Weight-Based Dosing Paradigm...
September 26, 2016 08:00 ET | Source: Bioblast Pharma

Bioblast’s Special Medical Advisor to Make a Presentation Today On Trehalose as a Potential Therapeutic Agent for OPMD

TEL AVIV, Israel, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced that Zohar Argov, MD,...
September 12, 2016 06:00 ET | Source: Bioblast Pharma

Bioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy (OPMD) Patients

TEL AVIV, Israel, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of the Extension...
September 07, 2016 08:00 ET | Source: Bioblast Pharma

Bioblast Pharma Announces Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016

TEL AVIV, Israel, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced it will be featured as a...
August 25, 2016 08:00 ET | Source: Bioblast Pharma

Bioblast Pharma Reports Second Quarter 2016 Financial Results

TEL AVIV, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
June 09, 2016 06:00 ET | Source: Bioblast Pharma

Bioblast Pharma Updates Corporate Plans

Trehalose Phase 2b Trial in Oculopharyngeal Muscular Dystrophy (OPMD) On Track to Commence During the Second Half of 2016 Focus On Trehalose As a Potential Platform Corporate...
May 25, 2016 08:00 ET | Source: Bioblast Pharma Ltd.

Bioblast Pharma Reports First Quarter 2016 Financial Results

NEW HAVEN, Conn., May 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
April 14, 2016 16:05 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting

NEW HAVEN, Conn., April 14, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive...
March 17, 2016 07:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering

NEW HAVEN, Conn., March 17, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN) (the "Company" or "ORPN") announced that it has entered into definitive securities purchase agreements...
March 16, 2016 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Positive Final Results from HOPEMD Phase 2 Open-Label Clinical Study of Trehalose 90mg/mL IV Solution in Oculopharyngeal Muscular Dystrophy (OPMD)

NEW HAVEN, Conn., March 16, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD...